MAP2K7 and lung adenocarcinoma: In lung adenocarcinoma, EGFR mutation is one of the “driver” mutations, leading to constant activation of the PI3K/AKT and RAS/MEK/ERK pathways.40 In the present study, we found that TGIF2 phosphorylation triggered by EGFR/RAS/ERK signaling plays an important role in LUAD progression, which indicated that p-TGIF2 acts as an EGFR/ERK signaling-responsive factor to drive lung cancer development.